FTC Appeals Judge's Dismissal of Suit Against Illumina
The company’s $7.1 billion acquisition of a cancer-test developer will now be considered by the five-member commission.
The company’s $7.1 billion acquisition of a cancer-test developer will now be considered by the five-member commission.